Testicular Metastasis of Prostatic Adenocarcinoma after Ablatherm® Treatment

Marcelo Di Gregorio1, Marie-Cécile Nollevaux2, Lionel D’Hondt3 and Francis Lorge1

1Urology Department, CHU UCL Namur, Belgium
2Anatomo-pathology, Department, CHU UCL Namur, Belgium
3Oncology Department, CHU UCL Namur, Belgium

*Corresponding author: Marcelo Di Gregorio, M.D., Urology Department, CHU UCL Namur, 1 Av Gaston Thérasse, B-5530 Yvoir, Belgium, Tel: +32 81 42 34 78; Fax: +32 81 42 34 79; E-mail: marcelo.digregorio@uclouvain.be

Received date: January 02, 2017; Accepted date: February 01, 2017; Published date: February 06, 2017

Copyright: © 2017 Di Gregorio M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Testicular metastases are rare in prostatic adenocarcinomas. The discovery is often fortuitous, and they are diagnosed with a histological examination. Metastasis is often confused with a primitive testicular tumor. We describe an 86-year-old patient with metastatic prostate adenocarcinoma that affected the left testis. The metastasis was discovered after Ablatherm® treatment. A prostatic origin must be suspected in a patient over 50 years old with testicular metastasis. This study highlights the importance of clinicopathological investigation and immunohistochemistry in determining the etiopathogenesis of testicular masses.

Keywords: Adenocarcinoma; Prostate; Metastatic; Testis

Abbreviations HIFU: High Intensity Focus Ultrasound; PC: Prostate Cancer; PSA: Prostatic Specific Antigen; LDH: Lactic Dehydrogenase; αFP: Alpha-Fetoprotein; βHCG: Beta Hormone Chorionic Gonadotropin; PSAP: Prostatic Acid Phosphatase; LH-RH: Luteinizing Hormone-Releasing Hormone; MRI: Magnetic Resonance Imaging; CAB: Combined Androgen Blockade; GnRH: Gonadotropin Releasing Hormone

Introduction

Prostate cancer is currently one of the highest health prevalent problems in developed countries. The treatments currently validated for prostate adenocarcinoma include surveillance, radical prostatectomy, external or interstitial radiation therapy, high intensity focused ultrasound (HIFU), hormonal therapy, and chemotherapy, depending on the stage.

The prognosis of prostate cancer is determined by the histologic grade and by the presence or absence of metastasis with pelvis lymph node involvement. The most common site of prostate cancer metastasis is the bone, particularly bones in the axial skeleton and the proximal long bone, which account for more than 90% of distant metastases [1]. Metastases are also found regularly in visceral locations (lung, liver, adrenal glands) [2]. Other locations are rare, and they are typically described in case reports.

Prostate cancer metastases can occur years after the diagnosis and initial treatment of the disease. Both synchronous and metachronous metastases to the testis are currently rare. The incidence was more outstanding previously, when the disease was treated with a bilateral orchietomy (surgical castration) [3].

Testicular metastasis of prostate adenocarcinoma is recognized as an advanced disease. It is often associated with metastases in other tissues or organs, particularly bones. Only 80 cases of testicular metastasis have been reported in the literature [4].

Here, we describe an 86-year-old patient that presented with a single metastasis in the left testis, 6 years after treatment with HIFU. The patient subsequently presented with a biochemical recurrence. He is currently receiving treatment with hormone therapy. We describe his clinical status 5 years after orchietomy left.

Clinical Case

A patient, aged 86, with no particularly relevant medical history, was referred in August 2004, due to an elevated PSA (5.2 ng/ml, 17% ratio). Prostatic biopsies revealed prostatic adenocarcinoma with a Gleason score of 6 (3+3)-grade I following the 2016 WHO new grading system. The proposed treatment was a transurethral resection of the prostate, followed by treatment with HIFU Ablaterm® because the patient was 71 years old and he had a LUTS due to a prostatic enlargement. Pathologic analysis did not reveal any tumoral cell.

Six years later, the clinical and laboratory follow up highlighted a biochemical recurrence (PSA doubling time <1 year). PSA rose from 1.7 in August 2009 to 3.4 ng/ml 7 months later. Clinical (digital rectal and testis examination) and radiologic (Cerebral CT, thoracoabdominal CT and Total body MRI), assessments were negative. Treatment was then started with anti-androgen (Bicalutamide 150 mg).

One year after the start of anti-androgen treatment, the patient complained of scrotal discomfort and an increase in volume. A clinical control visit revealed left testicular swelling. A testicular ultrasound showed a lesion of 7 mm × 10 mm × 12 mm, which appeared hypoechoic, heterogeneous, and vascularized, with micro-calcifications (Figure 1a and 1b). Renal function was normal. Serum tumor markers, including lactate dehydrogenase (LDH), alpha-fetoprotein (αFP), and the beta fraction of chorionic gonadotropin (βhCG), were normal. A scrotal exploration was performed via the left inguinal route, followed by a radical orchietomy.
Histological analysis showed that the testis was infiltrated by a revamped neoplastic cell population; Gleason 7(4+3) corresponding to a grade 3 according to the 2016 WHO grading system. Neoplasia extended to the rete testis and epididymis. The tumor displayed a massive, cribiform or reticular architecture (Figure 2a). Immunohistochemistry (Figure 2b) showed that the tumor cells were diffusely positive for PSA and prostatic acid phosphatase (PSAP), which confirmed a prostate adenocarcinoma metastasis.

A subsequent work-up, including a MRI centered on the total spine and pelvis and a thoraco-abdominopelvic CT, showed negative results. A new hormonal treatment was initiated, with an LH-RH analog, Triptorelin (Decapeptyl), at 11.25 mg, every 3 months. Two years later, the patient presented a new increase in PSA (0.1 in October 2012 to 0.6 ng/dl six months later). Therefore, we added Bicalutamide (Casodex®) at 50 mg daily, to establish a complete hormonal blockade. Currently, the patient is clinically asymptomatic, without biological relapse (PSA 0.31 ng/ml), and a good quality of life 5 years after orchiectomy.

Written informed consent was obtained from the patient for the publication of this case report and the use of the accompanying images. A copy of the written consent is available for review by Editor-in-Chief of this journal.

Discussion

The choice of Ablaterm treatment was done because of concern about the collateral side effects of radiotherapy and radical prostatectomy. Abltherm is a minimally invasive treatment for patients more than 70 years old that was considered at that time as a good alternative treatment. In addition, Ablaterm doesn't preclude second line radiotherapy or surgery.

When a testicular lesion occurs in a patient over 50 years old, in the context of an unknown neoplastic hematologic pathology, the etiologic diagnosis is unclear; it could be a primary or secondary tumor. Other studies have shown that prostate cancer rarely metastasizes to the testicles; an autopsy study reported an incidence of about 0.02-2.5 % [3].

Secondary testicular lesions typically originate from, in order of frequency, lymphoma, acute leukemia, prostate, lung, kidney, melanoma, colon tumors, and esophageal cancer [1,5]. In 15% of cases, both testicles are affected [4]. The patient is typically asymptomatic, and the metastasis is often discovered incidentally after therapeutic orchiectomies or during autopsies. The metastatic spread to the testicles can occur in several ways. First, via retrograde migration into the lumen of the vas deferens. Second, it can spread through vascular or lymphatic routes. Third, it may occur as a direct, local extension of the prostate tumor. In the present case, we suspected a vascular spread, because the lesion also permeated the vascular bed in the vas deferens. However, we could not rule out a retrograde invasion, due to the invasion of the rete testis and the epididymis. In this case the absence of other metastatic localization than the testicular one could support
Testicular metastasis of prostatic adenocarcinoma is rare. They should be suspected when any testicular mass is detected in a patient with a history of carcinoma in the prostate. A total radical orchiectomy with histological and immunohistochemical analyses are essential for establishing the precise diagnosis.

Statement of Ethics
Informed consent was provided by the patient for publication of this case and for the dissemination of images. A copy of the written consent is available from the editor of the journal.

References